Catheterization and Cardiovascular Interventions

Volume 92, Issue 3 pp. 557-565

Valvular and Structural Heart Diseases

Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience

Serkan Asil MD,

Corresponding Author

Serkan Asil MD

[email protected]

orcid.org/0000-0002-6782-4237

Department of Cardiology, Gülhane Education and Research Hospital, Ankara, Turkey

Correspondence Serkan Asil, MD, Gülhane Education and Research Hospital, Department of Cardiology, Ankara, Turkey. Email: [email protected]Search for more papers by this author

Barış Kaya MD,

Barış Kaya MD

Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Uğur Canpolat MD,

Uğur Canpolat MD

Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Hikmet Yorgun MD,

Hikmet Yorgun MD

Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Levent Şahiner MD,

Levent Şahiner MD

Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Cem Çöteli MD,

Cem Çöteli MD

Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Anıl Arat MD,

Anıl Arat MD

Department of Radiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Kudret Aytemir MD,

Kudret Aytemir MD

Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Serkan Asil MD,

Corresponding Author

Serkan Asil MD

[email protected]

orcid.org/0000-0002-6782-4237

Department of Cardiology, Gülhane Education and Research Hospital, Ankara, Turkey

Correspondence Serkan Asil, MD, Gülhane Education and Research Hospital, Department of Cardiology, Ankara, Turkey. Email: [email protected]Search for more papers by this author

Barış Kaya MD,

Barış Kaya MD

Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Uğur Canpolat MD,

Uğur Canpolat MD

Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Hikmet Yorgun MD,

Hikmet Yorgun MD

Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Levent Şahiner MD,

Levent Şahiner MD

Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Cem Çöteli MD,

Cem Çöteli MD

Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Anıl Arat MD,

Anıl Arat MD

Department of Radiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

Kudret Aytemir MD,

Kudret Aytemir MD

Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Search for more papers by this author

First published: 05 December 2017

https://doi.org/10.1002/ccd.27442

Citations: 4

Share a link

Email
Wechat
Bluesky

Abstract

Aims

Percutaneous septal reduction therapy by either alcohol or nonalcohol agents is an alternative approach to surgery in drug-refractory symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). Nonalcohol agents have some advantages and disadvantages over alcohol during the procedure. Nowadays, a novel non-alcohol agent, named as Ethylene-vinyl alcohol (EVOH) copolymer (Onyx^® and Squid^®), is used during septal ablation. Thus, in this study, we aimed to evaluate both acute and long-term efficacy and safety profile of EVOH during septal ablation in HOCM.

Methods and results

A total of 25 patients (52% female; mean age: 55.8 ± 17.1 years) with symptomatic HOCM were enrolled in the study. All subjects underwent clinical and laboratory assessment before and after the procedure. Peak left ventricular outflow tract (LVOT) gradient was significantly reduced just after the procedure (68 vs. 20 mmHg; P < 0.001). Peak serum creatine kinase-myocardial band and troponin I levels were 112 (35–282) ng/ml and 11 (4–93) ng/ml. EVOH embolization to diagonal artery was observed in 1 patient (4%) and the complete atrioventricular block was noted in 2 (8%) patients. During the 12-month follow-up, there was no mortality. There was a significant improvement in New York Heart Association functional class of the subjects P < 0.001). Both interventricular septum thickness and LVOT gradient showed a significant reduction during follow-up (P < 0.05). However, there was no reduction in the LVOT gradient of 3 patients (12%).

Conclusions

In conclusion, our small-sized preliminary study results showed that septal reduction therapy using EVOH is an effective alternative option in reducing symptoms and LVOT gradient in HOCM.

CONFLICT OF INTEREST

None declared.

REFERENCES

1 Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the American Association for Thoracic Surgery, American Society of echocardiography, American Society of nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58: e212–ee60.
10.1016/j.jacc.2011.06.011
CAS PubMed Web of Science® Google Scholar
2 Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014;ehu284.
Google Scholar
3 Fifer MA, Sigwart U. Hypertrophic obstructive cardiomyopathy: Alcohol septal ablation. Eur Heart J 2011; 32: 1059–1064.
10.1093/eurheartj/ehr013
PubMed Web of Science® Google Scholar
4 Veselka J, Lawrenz T, Stellbrink C, Zemanek D, Branny M, Januska J, Groch L, Dimitrow P, Krejci J, Dabrowski M, Mizera S, Kuhn H. Low incidence of procedure-related major adverse cardiac events after alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. Can J Cardiol 2013; 29: 1415–1421.
10.1016/j.cjca.2013.04.027
PubMed Web of Science® Google Scholar
5 Holmes DR, Valeti US, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: Indications and technique. Catheter Cardiovasc Interv 2005; 66: 375–389.
10.1002/ccd.20500
PubMed Web of Science® Google Scholar
6 Oto A, Aytemir K, Deniz A. New approach to septal ablation: Glue (cyanoacrylate) septal ablation. Catheter Cardiovasc Interv 2007; 69: 1021–1025.
10.1002/ccd.21003
CAS PubMed Web of Science® Google Scholar
7 Oto A, Aytemir K, Okutucu S, Kaya E, Deniz A, Cil B, Peynircioglu B, Kabakci G. Cyanoacrylate for septal ablation in hypertrophic cardiomyopathy. J Interv Cardiol 2011; 24: 77–84.
10.1111/j.1540-8183.2010.00605.x
PubMed Web of Science® Google Scholar
8 Szajner M, Roman T, Markowicz J, Szczerbo-Trojanowska M. Onyx^® in endovascular treatment of cerebral arteriovenous malformations–a review. Pol J Radiol 2013; 78: 35.
10.12659/PJR.889120
PubMed Google Scholar
9 Ayad M, Eskioglu E, Mericle RA. Onyx^®: A unique neuroembolic agent. Expert Rev Med Devices 2006; 3: 705–715.
10.1586/17434440.3.6.705
CAS PubMed Web of Science® Google Scholar
10 Gore P, Theodore N, Brasiliense L, Kim LJ, Garrett M, Nakaji P, Gonzalez LF, McDougall CG, Albuquerque FC. The utility of onyx for preoperative embolization of cranial and spinal tumors. Neurosurgery 2008; 62: 1204–1212.
10.1227/01.neu.0000333292.74986.ac
Web of Science® Google Scholar
11 Lang R, Bierig M, Devereux R, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79–108.
10.1016/j.euje.2005.12.014
CAS PubMed Web of Science® Google Scholar
12 Faber L, Seggewiss H, Welge D, et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr 2004; 5: 347–355.
10.1016/j.euje.2004.01.001
PubMed Google Scholar
13 Reinhard W, Ten Cate FJ, Scholten M, de Laat LE, Vos J. Permanent pacing for complete atrioventricular block after nonsurgical (alcohol) septal reduction in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol 2004; 93: 1064–1066.
10.1016/j.amjcard.2003.12.065
PubMed Web of Science® Google Scholar
14 Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A systematic review of published studies. J Interv Cardiol 2006; 19: 319–327.
10.1111/j.1540-8183.2006.00153.x
CAS PubMed Google Scholar
15 Veselka J, Lawrenz T, Stellbrink C, et al. Early outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A European multicenter and multinational study. Catheter Cardiovasc Interv 2014; 84(1): 101–107.
10.1002/ccd.25236
PubMed Web of Science® Google Scholar
16 Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, Bartelsmeier M, Stellbrink C. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): A 10 year experience. Clin Res Cardiol 2008; 97: 234–243.
10.1007/s00392-007-0616-7
PubMed Web of Science® Google Scholar
17 Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, Hodge DO, Schaff HV, Holmes DR. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008; 118: 131–139.
10.1161/CIRCULATIONAHA.107.738740
PubMed Web of Science® Google Scholar
18 Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A systematic review of published studies. J Interv Cardiol 2006; 19: 319–327.
10.1111/j.1540-8183.2006.00153.x
CAS PubMed Google Scholar
19 Veselka J, Lawrenz T, Branny M, Sitar J, Dimitrow P, Krejci J, Dabrowski M, Mizera S, Bartel T, Stellbrink C. Outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A European multicentre and multinational study. Eur Heart J 2013; 34: P2177.
10.1093/eurheartj/eht308.P2177
Web of Science® Google Scholar
20 Fifer MA, Yoerger DM, Picard MH, Vlahakes GJ, Palacios IF. Covered stent septal ablation for hypertrophic obstructive cardiomyopathy initial success but ultimate failure resulting from collateral formation. Circulation 2003; 107: 3248–3249.
10.1161/01.CIR.0000068035.52761.71
PubMed Web of Science® Google Scholar
21 Gross CM, Schulz-Menger J, Krämer J, Siegel I, Pilz B, Waigand J, Friedrich MG, Uhlich F, Dietz R. Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: Acute and 3-year outcomes. J Endovasc Ther 2004; 11: 705–711.
10.1583/03-1171MR.1
PubMed Web of Science® Google Scholar
22 Lawrenz T, Borchert B, Leuner C, Bartelsmeier M, Reinhardt J, Strunk-Mueller C, Meyer Zu Vilsendorf D, Schloesser M, Beer G, Lieder F, Stellbrink C, Kuhn H. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: Acute results and 6 months' follow-up in 19 patients. J Am Coll Cardiol 2011; 57: 572–576.
10.1016/j.jacc.2010.07.055
PubMed Web of Science® Google Scholar
23 Durand E, Mousseaux E, Coste P, et al. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: Early and 6 months follow-up. Eur Heart J 2008; 29(3): 348–355.
10.1093/eurheartj/ehm632
PubMed Web of Science® Google Scholar
24 Folkert J, Soliman OI, Michels M, et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy. Circ Heart Fail 2010; 3: 362–369.
10.1161/CIRCHEARTFAILURE.109.862359
PubMed Web of Science® Google Scholar
25 Smedira NG, Lytle BW, Lever HM, Rajeswaran J, Krishnaswamy G, Kaple RK, Dolney DOW, Blackstone EH. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 2008; 85: 127–133.
10.1016/j.athoracsur.2007.07.063
PubMed Web of Science® Google Scholar
26 Xin J, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JK, Martin M, Tuzcu M, Smedira NG, Lytle B, Thomas JD. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery12. J Am Coll Cardiol 2001; 38: 1994–2000.
10.1016/S0735-1097(01)01656-4
PubMed Web of Science® Google Scholar
27 Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up. J Am Coll Cardiol 2000; 36: 852–855.
10.1016/S0735-1097(00)00767-1
CAS PubMed Web of Science® Google Scholar
28 Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: A meta-analysis. Eur Heart J 2009; 30(9): 1080–1087.
10.1093/eurheartj/ehp016
PubMed Web of Science® Google Scholar
29 Okutucu S, Aytemir K, Oto A. Glue septal ablation: A promising alternative to alcohol septal ablation. JRSM Cardiovasc Dis 2016; 5: 2048004016636313.
10.1177/2048004016636313
Web of Science® Google Scholar
30 van Dockum WG, Beek AM, Folkert J, et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2005; 111: 2503–2508.
10.1161/01.CIR.0000165084.28065.01
PubMed Web of Science® Google Scholar
31 Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, Dabrowski M, Hansen PR, Almaas VM, Seggewiss H, Horstkotte D, Tomasov P, Adlova R, Bundgaard H, Steggerda R, ten Berg J, Faber L. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: Results from the Euro-ASA registry. Eur Heart J 2016; 37: 1517–1523.
10.1093/eurheartj/ehv693
PubMed Web of Science® Google Scholar
32 Deb SJ, Schaff HV, Dearani JA, Nishimura RA, Ommen SR. Septal myectomy results in regression of left ventricular hypertrophy in patients with hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 2004; 78: 2118–2122.
10.1016/j.athoracsur.2004.05.063
PubMed Web of Science® Google Scholar
33 Dąbrowski M, Chojnowska L, Małek L, et al. An assessment of regression of left ventricular hypertrophy following alcohol ablation of the interventricular septum in patients with hypertrophic cardiomyopathy with left ventricular outflow tract obstruction. Kardiol Pol 2011; 70: 782–788.
Web of Science® Google Scholar
34 Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, Conte MR, Casazza F, Galderisi M, Maron BJ, Cecchi F. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol 2006; 98: 960–965.
10.1016/j.amjcard.2006.05.013
PubMed Web of Science® Google Scholar

Citing Literature

Volume92, Issue3

September 1, 2018

Pages 557-565

SCAI Member Sign in

Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience

Abstract

Aims

Methods and results

Conclusions

CONFLICT OF INTEREST

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience

Abstract

Aims

Methods and results

Conclusions

CONFLICT OF INTEREST

REFERENCES

Citing Literature

References

Related

Information